Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Eventbrite, Raises Price Target to $10

Morgan Stanley Maintains Equal-Weight on Eventbrite, Raises Price Target to $10

Morgan Stanley analyst Benjamin Swinburne maintains Eventbrite (NYSE:EB) with a Equal-Weight and raises the price target from $9 to $10.

byBenzinga Newsdesk

March 2, 2023

1 minute read

Morgan Stanley analyst Benjamin Swinburne maintains Eventbrite (NYSE:EB) with a Equal-Weight and raises the price target from $9 to $10.

Scotiabank Downgrades Anaergia to Sector Perform, Lowers Price Target to C$7.25

By Benzinga Newsdesk

November 30, 9:50 AM

Scotiabank analyst Justin Strong downgrades Anaergia (TSX:ANRG) from Outperform to Sector Perform and lowers the price target from C$14.5 to C$7.25.

TSX:ANRG

Boeing Stock Takes Off After US Aviation Bill Passes, But Possible Turbulence Ahead With Legal Uncertainties

By Surbhi Jain

May 16, 12:03 PM

Boeing faces regulatory changes, legal challenges, and mixed technical signals. While an aviation bill offers hope, DOJ's warning adds uncertainty.

Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial

By Vandana Singh

December 14, 1:10 PM

Avidity Biosciences Inc (NASDAQ:RNA) announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever…

RNA

Legal
News

Clarivate And OCLC Settle Lawsuit

By Benzinga Newsdesk

November 7, 2:29 PM

Speedy resolution in best interests of libraries and ensures fair competition for both LONDON, Nov. 7, 2022 /CNW/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and

CLVT

Morgan Stanley Maintains Equal-Weight on Eventbrite, Raises Price Target to $10

Related Posts

Scotiabank Downgrades Anaergia to Sector Perform, Lowers Price Target to C$7.25

Boeing Stock Takes Off After US Aviation Bill Passes, But Possible Turbulence Ahead With Legal Uncertainties

Avidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial

Clarivate And OCLC Settle Lawsuit